Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 372446
The Licensee acknowledges Licensors role as the co-inventor of the invention and therefore that she had a right to be the co-owner of the patent and its international extensions which protect the device for the intraocular transfer of active substances by iontophoresis.
By this agreement, Licensor of France renounces her right to take action against the Licensee of the Netherlands for recovery of the registered patents.
Certain patents with respect to and which are used in Licensee's EGP-437 Combination Product.
US patent application NÂ°09/225,206 (now granted, NÂ° 6,154,671)
Iontophoresis is a process of transdermal drug delivery by use of a voltage gradient on the skin.
EGP-437 in clinical trials, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues though our proprietary innovative drug delivery system, the EyeGateÂ® II Delivery System.
The EyeGateÂ® II Delivery System and EGP-437, are designed to address two major issues in ophthalmic medicine lack of patient compliance and safety. The EyeGateÂ® II Delivery System features a compact, elegant, and easy-to-use device that we believe has the potential to deliver drugs non-invasively and quickly into the ocular tissues through the use of iontophoresis, which can accelerate the onset of action, dramatically reduce treatment frequency versus eye drops and sustain therapeutic effect. Iontophoresis employs the use of a low electrical current that promotes the migration of a charged drug substance across biological membranes.
IPSCIO Record ID: 260371
Licensor grants the authority to make any application for patents, including patent applications related to Scientific Results, in the name of Licensee; all expenses of obtaining and maintaining said patents shall be paid by Licensee.
IPSCIO Record ID: 2759
The Licensee has developed and produced the first FDA – approved electronically controlled transdermal drug delivery system that transports drugs through the skin comfortably, without needles. Our active transdermal drug delivery technology is based on a process known as electrotransport, or more specifically iontophoresis, a process that transports drugs, including peptides, through the skin by applying a low-level electrical current. Our active patch patented technology works by applying a charge to the drug-holding reservoir of the patch. This process differs significantly from passive transdermal drug delivery which relies on the slow, steady diffusion of drugs through the skin. A significantly greater number of drugs can be delivered through active transdermal delivery than is possible with passive transdermal delivery. Based on our analysis thus far, we estimate that there are currently over 220 FDA-approved drugs that may be delivered through our active transdermal delivery platform.